Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 2, 2021Acquisition builds upon Abbott's leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots
- Aug 30, 2021- New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device- Amulet device is the first and only minimally invasive option approved for LAA occlusion that does not require blood-thinning medication following implantation- Trial results supported recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation
- Aug 27, 2021- The GUIDE-HF study examined the potential impact of Abbott's CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device- Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease
- Aug 16, 2021- Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation- The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with atrial fibrillation, the most common sustained cardiac arrhythmia
- Aug 3, 2021- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence- The new intuitive interface provides step-by-step guidance to enhance ease of use- When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care
Aug 2, 2021- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon-
Jul 29, 2021- Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott's connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic- Jot Dx™ ICM connects via Bluetooth with Abbott’s myMerlin™ mobile app for continuous remote monitoring, leading to a faster time to diagnosis compared to ICMs that may use traditional bedside monitors1- Abbott’s personalized concierge service, SyncUp™, provides one-on-one device setup support, helping patients connect Jot Dx™ ICM with the mobile app at home, taking the burden off physicians and clinic staff
- Jul 29, 2021- Patients with diabetes who did not meet the recommended daily intake of protein had greater physical limitations, which together may suggest an increased risk of muscle loss- Abbott's line of nutrition products scientifically designed for people with diabetes now includes Glucerna® 30g protein shakes to help people with diabetes meet important daily protein consumption goals
- Jul 22, 2021- Sales growth of 39.5 percent; organic sales growth of 35.0 percent- GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent- Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019- Achieved strong sales growth across all four major business areas- Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
- Jun 30, 2021- New labeling approval for Abbott's XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR)- The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval in Europe- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants
-
Jun 28, 2021- Panbio™ COVID-19 Antigen Self-Test is approved for sale directly to consumers and for use in adults and children with or without symptoms, enabling fast, convenient coronavirus testing- The self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- In clinical evaluations with self-test users, the Panbio Self-Test correctly identified 95.2% of positive samples and 100% of negative samples- Abbott is the only diagnostics manufacturer to provide performance data on a rapid antigen test specific for use on children who are 15 years and younger, including infants- Together with vaccines and health protocols, frequent, regular screening of asymptomatic and symptomatic people can restore a sense of safety and stability as more people return to work, school, family gatherings and recreational activities
- Jun 25, 2021- Comparative data presented at the American Diabetes Association 81st Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population- Priced at a third of the cost of other available continuous glucose monitoring systems(3), data suggests increasing use of FreeStyle Libre system could save Medicaid millions annually(4) by reducing costly complications- The groundbreaking FreeStyle Libre portfolio has been extensively studied with real-world data from more than 1 million users(5) and clinical evidence, showing it helps people with diabetes significantly improve their health and quality of life(6)
- Jun 24, 2021- Survey reveals nearly half of people who report regular, intense exercise believe that energy drinks and soda can aid in rehydration after exercising; however, these beverages do not meet scientific experts' recommendations for rehydration¹,²,³- Abbott, maker of Pedialyte®, teams up with fitness coach Jeanette Jenkins to encourage smart hydration
Jun 22, 2021Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit- Abbott's summer program is the American Council on Education's first high school STEM internship eligible for post-secondary education credit recommendation- First-of-its-kind college credit opportunity provides model other companies can follow to give students a head start on earning STEM degrees- Students who successfully complete Abbott's internship after their senior year of high school are eligible to apply for credit from their educational institutions-
Jun 7, 2021- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation- New delivery system works with Abbott's leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and seals off a broad range of LAA anatomies- Steerable sheath gives physicians enhanced flexibility and precise placement when implanting Amplatzer Amulet
-
Jun 7, 2021- All 16 Walgreens locations in the city of Philadelphia will provide the rapid BinaxNOW™ COVID-19 Antigen Self Test at no cost to customers who present a Pennsylvania EBT ACCESS Card, starting June 7 and running through July 4- First-of-its-kind pilot program aims to increase consumer access to rapid testing- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and has been available nationwide for over-the-counter (OTC), non-prescription purchase at Walgreens since mid-April
- Jun 3, 2021- Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD)- Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life- Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) alongside training and education for implanting physicians now offering Abbott's HeartMate 3™ to their patients
- Jun 1, 2021- Updated outlook reflects lower recent and projected demand for COVID-19 tests- Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis- Abbott's base business, excluding COVID-19 testing-related sales, continues to achieve strong growth- R&D pipeline continues to be highly productive, with a steady cadence of recent and upcoming product launches across the portfolio
-
May 18, 2021Addressing High Blood Pressure to Reduce Health Disparities in Central Texas Underserved Communities- American Heart Association and Abbott announce new initiative to advance health equity, fight high blood pressure and chronic conditions in greater Austin area
- May 17, 2021- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
-
May 12, 2021- Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria- United customers can depart the U.S. with the Abbott BinaxNOW™ Home Test in their carry-on bag and administer the test via the eMed digital health platform to re-enter the U.S.
- May 6, 2021- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure- The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats- Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously